In a recent phase I clinical trial, DCs were pulsed with three distinct HLA-A2-restricted tumor peptides (hTERT, carcinoembryonic antigen and survivin) and administered to 12 patients with advanced pancreatic cancer. This evidence concerns the gene BIRC5 and neoplasm.